Tuberous Sclerosis Complex Financial Planning: Medicaid Preservation, Everolimus Costs, and SNT Strategy

Tuberous sclerosis complex (TSC) is a genetic condition where benign tumors grow in the brain, kidneys, lungs, skin, and other organs — and where the financial planning challenge is complicated by a wide spectrum of severity that ranges from nearly invisible to profoundly disabling. For families whose affected family member requires mTOR inhibitor therapy, Medicaid preservation sits at the center of the financial plan: brand everolimus (Afinitor) carries a list price exceeding $200,000 per year for TSC-related brain tumors and kidney disease, and even with generic competition now available, insurance continuity determines whether treatment continues. For higher-functioning TSC adults who work and manage epilepsy with medication alone, the planning challenges are different — work incentives, ABLE accounts, and a careful approach to SSI thresholds that allow Medicaid to persist even when cash benefits phase out. Both populations need a financial plan. Neither gets a simple one.

The TSC spectrum: why severity determines the financial plan

TSC is caused by mutations in either the TSC1 gene (hamartin) or the TSC2 gene (tuberin), both of which regulate the mTOR signaling pathway. TSC2 mutations are associated with more severe disease than TSC1 mutations, though within each gene there is wide variability in expression. Approximately one-third of TSC cases are inherited from an affected parent; two-thirds arise from de novo mutations.¹

The numbers that define the TSC planning landscape, based on published cohort studies:²

The population of people in the United States with TSC is estimated at approximately 40,000–50,000.³ Because the condition ranges from very mild (skin findings and well-controlled epilepsy, full employment, normal intellectual functioning) to severe (refractory epilepsy, significant intellectual disability, multiple organ involvement), TSC families span every income and asset level. The financial planning needs of a mild-presentation adult who has worked their entire life are completely different from those of a family managing a severely affected child.

The treatments driving Medicaid preservation for TSC

For a subset of TSC patients — those with SEGAs, renal AMLs, or TSC-associated partial-onset seizures — mTOR inhibitor therapy is FDA-approved and clinically indicated. The cost of these treatments makes Medicaid a critical planning asset.

Everolimus (Afinitor, Afinitor Disperz) for SEGAs, renal AMLs, and epilepsy

Everolimus was approved by FDA for TSC-associated SEGA tumors in 2010, for TSC-associated renal AMLs in 2012, and for TSC-associated partial-onset seizures (adjunctive therapy) in 2018. It is the primary disease-modifying treatment for TSC patients with these specific manifestations.⁴

Brand Afinitor's list price exceeds $200,000 per year — some sources cite approximately $18,000–$24,000 per 28-day supply, placing the annual brand cost between $240,000 and $315,000 depending on strength and formulation.⁵ In January 2025, Amneal Pharmaceuticals received FDA approval for the first generic everolimus oral suspension for TSC-related SEGA, which introduces a lower-cost alternative — but generic pricing remains subject to pharmacy and insurer negotiation, and the list price discount may not fully materialize in out-of-pocket terms without insurance coverage.

Novartis offers an oncology co-pay assistance program (Novartis Oncology Universal Co-Pay Program) for commercially insured patients that can reduce out-of-pocket costs significantly. But co-pay assistance programs are unavailable to Medicaid enrollees — meaning Medicaid itself must be the payer for those on means-tested benefits. For a TSC family where the affected member receives SSI and Medicaid, a resource limit violation that destroys SSI eligibility can simultaneously cut off Medicaid access to a treatment that, at list price, would cost the family $240,000+ per year out of pocket.

Sirolimus (Rapamune) for TSC-associated LAM

Sirolimus received FDA approval in 2015 specifically for lymphangioleiomyomatosis (LAM), the pulmonary condition that affects approximately 30–40% of reproductive-age women with TSC and causes progressive cystic lung destruction. It was the first FDA-approved treatment for LAM — which, like everolimus, targets the mTOR pathway.⁶

Brand Rapamune (sirolimus) can cost $1,000–$3,400+ per month — roughly $12,000–$40,000 per year — at standard dosing. Unlike everolimus, generic sirolimus has been available for longer and is more accessible: generic sirolimus can cost as little as $165–$500 per month (approximately $2,000–$6,000 per year) at retail pharmacies, and significantly less with assistance programs. For women with TSC-associated LAM, the ongoing sirolimus treatment cost is real but often manageable with commercial insurance or Medicaid coverage. The financial planning issue becomes critical when LAM advances to the point of significant lung function decline and potential lung transplant: lung transplant hospitalization and recovery costs range from $200,000 to $1 million or more, and post-transplant medications are lifelong.

Section 1619(b): the working TSC adult's Medicaid bridge

For TSC adults who receive SSI and work — a meaningful population, since approximately 30–40% of TSC adults have normal or near-normal intellectual functioning — Section 1619(b) is the critical provision that allows them to earn above the Substantial Gainful Activity level ($1,690/month in 2026) while retaining Medicaid coverage. This matters because even if the individual earns enough to disqualify them from SSI cash payments, Medicaid continuity is preserved as long as earnings remain below the state threshold (which ranges from approximately $29,000 to $84,000 per year, varying by state). For a working TSC adult who uses everolimus or sirolimus, losing Medicaid would transform a manageable out-of-pocket cost into a financial emergency.

SSDI and SSI qualification pathways for TSC

Tuberous sclerosis complex does not appear on SSA's Compassionate Allowances list and has no dedicated Blue Book impairment listing. Instead, SSA evaluates TSC claims under whichever existing listings match the individual's symptoms and functional limitations. Most TSC individuals who qualify do so through one of three pathways — often with overlap.⁷

Pathway 1: Blue Book Listing 11.02 (Epilepsy)

Since 75–85% of people with TSC have epilepsy, Listing 11.02 is the most commonly applicable pathway for those with significant seizure burden. The listing has four sub-criteria:⁸

Many TSC individuals with refractory epilepsy — approximately 30–40% of those with TSC-related epilepsy do not achieve full seizure control with standard AEDs — meet 11.02A or 11.02B. The documentation challenge is demonstrating that seizures persist "despite adherence to prescribed treatment," which requires a seizure log and treating neurologist attestation. For a TSC patient, everolimus may have been added as adjunctive antiepileptic therapy; the claim should note this high-cost treatment and the seizure frequency before and after it was added.

TSC adults with well-controlled epilepsy (rare but possible with optimal medication management, dietary therapies, or vagus nerve stimulator) who have no intellectual disability and no other significant functional limitations may not qualify under 11.02. These higher-functioning adults typically need a Residual Functional Capacity evaluation (see below).

Pathway 2: Blue Book Listing 12.05 (Intellectual Disorder)

Approximately 50–68% of people with TSC have intellectual disability. Listing 12.05 requires:⁸ (1) significantly subaverage general intellectual functioning (IQ ≤70 and substantial deficits in adaptive functioning, or IQ 71–75 with evidence of onset before age 22 and a highly significant deficit in one adaptive area); (2) extreme or marked limitations in at least two functional areas from the "paragraph B" criteria (understanding/applying information, interacting with others, concentrating/persisting, and self-management). Because TSC-related intellectual disability typically arises from early childhood epilepsy and brain tuber burden, Listing 12.05 with onset before age 22 is usually straightforward to document for those with significant ID.

Pathway 3: Blue Book Listing 12.10 (Autism Spectrum Disorder)

For the approximately 33–42% of TSC individuals with comorbid autism spectrum disorder, Listing 12.10 provides an alternative qualification pathway if the ASD presentation is functionally limiting. The listing requires deficits in social communication/interaction and restricted/repetitive behaviors, with at least one extreme limitation or two marked limitations across the paragraph B functional areas. ASD-presenting TSC adults may qualify under 12.10 even when their epilepsy is well-controlled, because the social communication and adaptive functioning deficits may be independently disabling.

RFC approach for functioning TSC adults

For TSC adults who don't clearly meet any listing — for example, a person with mild TSC, controlled epilepsy with few breakthrough seizures, normal intelligence, but recurring medical appointments, AED side effects (cognitive slowing, fatigue, behavioral changes), and driving restrictions that limit employment — SSA uses a Residual Functional Capacity (RFC) evaluation. The RFC documents what the person can still do despite their limitations and compares that profile to available jobs. RFC claims for TSC often rest on:

• Driving restrictions from seizure precaution periods (typically 3–18 months seizure-free per state law) that limit transportation and job access
• AED cognitive side effects (topiramate, in particular, carries well-documented cognitive slowing) that impair memory, concentration, and processing speed
• Post-ictal fatigue and recovery time after breakthrough seizures that make attendance requirements unreliable
• Appointment and monitoring burden (brain MRI every 1–3 years for SEGA surveillance, renal ultrasound or CT every 1–3 years, ophthalmologic exams, pulmonary function testing for women)

RFC claims require a detailed disability attorney or advocate who understands how to translate TSC's symptom burden into functional limitations. The RFC approach typically takes longer than a listing approval and often requires appeal.

Disabled Adult Child (DAC) benefits

A person with TSC who became disabled before age 22 — as most individuals with moderate-to-severe TSC do, given childhood epilepsy onset — is eligible for Disabled Adult Child (DAC) benefits on a parent's Social Security earnings record when the parent retires, becomes disabled, or dies. DAC benefits are 50% of the parent's Primary Insurance Amount (PIA) while the parent is alive and 75% upon the parent's death.⁹ DAC benefits can reach $1,500–$2,800+ per month for parents with average to above-average earnings, substantially exceeding the 2026 SSI Federal Benefit Rate of $994 per month. DAC benefits trigger Medicare after a 24-month waiting period, which may supplement or replace Medicaid as the insurance payer for everolimus — though Medicaid provides broader coverage and does not impose a deductible, making it preferable for high-cost treatments in many states.

Kidney disease planning: renal AMLs and the failure risk

Renal angiomyolipomas (AMLs) — benign tumors of fat, muscle, and blood vessels — occur in approximately 55–80% of people with TSC and are the leading cause of TSC-related kidney complications. AMLs can grow throughout life, and tumors larger than 3 cm in diameter carry a risk of spontaneous hemorrhage.¹ Three planning considerations are unique to TSC renal disease:

1. Everolimus as first-line for AML ≥3 cm: Current TSC management guidelines recommend everolimus (Afinitor) as the preferred treatment for AMLs ≥3 cm that are at risk for hemorrhage, rather than prophylactic embolization. This FDA-approved indication is separate from the SEGA and epilepsy indications — a TSC patient might need everolimus for AMLs even if their epilepsy is controlled and they have no brain tumors. Again, Medicaid preservation is the financial planning tool that keeps this treatment accessible.
2. Embolization reserve: When AML hemorrhage occurs — or when AMLs must be treated emergently — transcatheter embolization is the preferred approach over nephrectomy. The procedure carries significant cost ($20,000–$60,000+ per event, depending on hospital setting and complexity) and may recur. An SNT with a specific embolization reserve line item addresses this.
3. Renal failure trajectory: A minority of TSC patients develop chronic kidney disease and end-stage renal disease from cumulative AML damage or multiple surgical interventions. Kidney failure substantially raises SNT funding requirements: dialysis costs $90,000–$100,000+ per year, and kidney transplant hospitalization costs $150,000–$300,000+. The SNT should include a protocol for the trustee to reassess funding targets annually as kidney disease progresses.

LAM planning for female TSC adults

Lymphangioleiomyomatosis (LAM), a progressive cystic lung disease driven by mTOR-activating mutations, occurs in approximately 30–40% of reproductive-age women with TSC. In many cases, LAM is asymptomatic or mild and managed with sirolimus without disrupting employment or daily function. In a subset of cases, LAM progresses to significant lung function decline requiring oxygen supplementation, work modification, and ultimately lung transplantation.⁶

Financial planning for women with TSC must include a LAM evaluation — specifically, pulmonary function testing and high-resolution CT screening. The planning implications depend on the severity:

Women with TSC who have LAM should secure individual life insurance and long-term disability coverage before LAM causes measurable FEV1 decline — underwriters may decline or rate-up policies once LAM progression is documented in medical records. The GINA protections that apply to health insurance do not extend to life or disability insurance, and LAM progression disclosed in a medical record can be used in underwriting decisions.

SNT sizing by TSC severity profile

The lifetime funding target for a Special Needs Trust supporting a TSC beneficiary varies more than almost any other condition, because TSC's presentation spans such a wide range. The table below uses present-value estimates at a 3% real discount rate for a beneficiary currently age 25, with a life expectancy projection to age 70, without accounting for HCBS waiver-funded services:¹⁰

Because TSC involves multiple organ systems that can progress independently — kidneys, brain, lungs — the trustee should have explicit authority in the trust document to commission an updated lifetime care plan every 3–5 years or following any significant change in medical status. The SNT funding target for TSC is not a fixed number; it should be recalibrated as the beneficiary ages and the disease trajectory becomes clearer.

Use the Lifetime Special Needs Care Cost Projection Calculator and the SNT Funding Calculator to build a preliminary estimate, then work with a specialist to adjust for TSC-specific medical cost overlays.

ABLE accounts for higher-functioning TSC adults

For TSC adults with onset of disability before age 46 — which covers all TSC individuals, since TSC is present from birth — ABLE accounts are available as of the January 2026 age-46 eligibility expansion (ABLE Age Adjustment Act). ABLE accounts allow up to $20,000 per year in contributions (plus additional amounts under the ABLE-to-Work provision for working account owners) that do not count against SSI's $2,000 resource limit for the first $100,000. For a working TSC adult managing ongoing medical expenses — AED co-pays, monitoring imaging, AED-related dental costs (gingival hyperplasia from phenytoin use), specialist visits, accessible transportation to medical appointments — an ABLE account provides a tax-advantaged vehicle to accumulate and spend these funds without jeopardizing SSI and Medicaid eligibility.

For TSC adults who receive SSI and use the Section 1619(b) protection to work, the ABLE-to-Work provision allows contributions above the standard $20,000 limit equal to the prior year's gross earnings (up to $15,650 in 2026). This substantially increases the ABLE accumulation capacity for a working TSC adult — enabling savings of $35,650 per year or more while maintaining Medicaid coverage through 1619(b).

Genetic planning: implications for family members

TSC is autosomal dominant with 50% inheritance probability per child of an affected parent. Approximately two-thirds of TSC cases are de novo mutations, but the one-third that are inherited carry planning implications for siblings and children of affected individuals. Key points for families:

• Carrier family members as trustees: An affected TSC parent who wants to serve as their child's SNT trustee should confirm that their own cognitive and functional trajectory is stable. TSC1/TSC2 mosaicism sometimes means a parent has very mild TSC that appears stable — but a specialist's assessment is appropriate before assuming decades of trustee capacity.
• Sibling testing: Unaffected siblings of a TSC child may have mild mosaic TSC or carry the TSC1/TSC2 mutation in a form that isn't yet visible. Genetic counseling for siblings before financial decisions (like purchasing life insurance) may preserve underwriting options.
• GINA protections for health insurance apply to TSC: The Genetic Information Nondiscrimination Act (GINA) prohibits use of TSC genetic test results in health insurance underwriting. GINA does not protect life insurance or long-term disability insurance — the same gap applicable to other genetic conditions like Huntington's disease. Family members who have had genetic testing confirming TSC1/TSC2 mutation carriage should secure life and LTD insurance before that information enters their medical record in a form insurers can see.

How to find a specialist

TSC financial planning requires a fee-only advisor who understands how multiple benefit systems interact — SSI/SSDI, Medicaid, HCBS waivers, and ABLE accounts — alongside complex medical cost modeling for a condition with widely variable severity. A generalist financial advisor who lacks benefits training will typically miss the Medicaid preservation issue entirely, and may recommend conventional estate planning (direct beneficiary designations, UTMA accounts) that destroys SSI eligibility.

The three-professional team for a TSC family is: a special needs financial planner (benefits coordination, SNT funding, life insurance structuring), a special needs trust attorney (drafting the trust, coordinating with the will and beneficiary designations), and a benefits counselor (SSI work incentives analysis, ABLE account setup, HCBS waiver application). The financial planner should have experience with TSC's specific manifestations — renal AML surveillance, SEGA monitoring, and LAM for female patients — because these organ-level issues affect the care cost model in ways a condition-agnostic planner will not know to ask about.

SpecialNeedsAdvisorMatch is a referral service, not a licensed advisory firm. We may receive compensation from professionals in our network. Content is for informational purposes only and does not constitute financial, tax, legal, or investment advice.